This is supported by recent findings showing that reduced sarcolemmal utrophin correlates with more severe clinical phenotypes in DMD patients, and that the failure of utrophin to localize to the membrane may underlie unusually severe disease in cases with in-frame dystrophin deletions [62,63]. This evidence concerns the gene DMD and Duchenne muscular dystrophy.